Madlen Gazarian1, Linda Velta Graudins. 1. Paediatric Therapeutics Program, School of Women’s and Children’s Health, University of New South Wales, New South Wales, Australia. m.gazarian@unsw.edu.au
Abstract
OBJECTIVES: To develop and test an evidence-based model for reducing medication errors and harm in hospitalized children. METHODS: Prospective interrupted time series study evaluating the effectiveness of a multifaceted, staged intervention over 4 years in a major urban pediatric referral hospital. Guidelines for safe pediatric prescribing were implemented by using an evidence-based model. Key components included early clinician engagement and improved multidisciplinary communication, consensus development, interactive education, and timely data feedback by using iterative Plan-Do-Study-Act cycles. Impact on medication error and harm (adverse drug events, [ADEs]) was measured by using standard definitions and a multimethod approach. Prospective data from voluntary reports by nursing, medical, and pharmacy staff and intensive chart review were combined. All data were reviewed by a multidisciplinary panel, including causality assessments for ADEs. RESULTS: Reviewed over 3 time periods were 1011 patients with 6651 medication orders. Total ADEs decreased by > 50% in the first year and this was maintained at 4 years. Greatest improvements were in potential ADEs, which decreased from 12.26 per 100 patients at baseline to 4.60 per 100 patients at 4 years (P < .05). Total medication errors decreased from 4.51 per 100 orders at baseline to 2.78 per 100 orders at 4 years (P < .05). Prescribing errors decreased by 65%, from 4.07 per 100 orders at baseline to 2.05 orders at 4 years (P < .05). CONCLUSIONS: A multifaceted, evidence-based model for safe prescribing guideline implementation, engaging multidisciplinary clinicians, was effective in reducing medication error and harm in hospitalized children, resulting in sustained long-term improvement.
OBJECTIVES: To develop and test an evidence-based model for reducing medication errors and harm in hospitalized children. METHODS: Prospective interrupted time series study evaluating the effectiveness of a multifaceted, staged intervention over 4 years in a major urban pediatric referral hospital. Guidelines for safe pediatric prescribing were implemented by using an evidence-based model. Key components included early clinician engagement and improved multidisciplinary communication, consensus development, interactive education, and timely data feedback by using iterative Plan-Do-Study-Act cycles. Impact on medication error and harm (adverse drug events, [ADEs]) was measured by using standard definitions and a multimethod approach. Prospective data from voluntary reports by nursing, medical, and pharmacy staff and intensive chart review were combined. All data were reviewed by a multidisciplinary panel, including causality assessments for ADEs. RESULTS: Reviewed over 3 time periods were 1011 patients with 6651 medication orders. Total ADEs decreased by > 50% in the first year and this was maintained at 4 years. Greatest improvements were in potential ADEs, which decreased from 12.26 per 100 patients at baseline to 4.60 per 100 patients at 4 years (P < .05). Total medication errors decreased from 4.51 per 100 orders at baseline to 2.78 per 100 orders at 4 years (P < .05). Prescribing errors decreased by 65%, from 4.07 per 100 orders at baseline to 2.05 orders at 4 years (P < .05). CONCLUSIONS: A multifaceted, evidence-based model for safe prescribing guideline implementation, engaging multidisciplinary clinicians, was effective in reducing medication error and harm in hospitalized children, resulting in sustained long-term improvement.
Authors: Peter J Gates; Melissa T Baysari; Madlen Gazarian; Magdalena Z Raban; Sophie Meyerson; Johanna I Westbrook Journal: Drug Saf Date: 2019-11 Impact factor: 5.606
Authors: Jacqueline M Bos; Patricia M L A van den Bemt; Peter A G M de Smet; Cornelis Kramers Journal: Br J Clin Pharmacol Date: 2017-01-12 Impact factor: 4.335
Authors: J I Westbrook; L Li; M Z Raban; M T Baysari; V Mumford; M Prgomet; A Georgiou; T Kim; R Lake; C McCullagh; L Dalla-Pozza; J Karnon; T A O'Brien; G Ambler; R Day; C T Cowell; M Gazarian; R Worthington; C U Lehmann; L White; D Barbaric; A Gardo; M Kelly; P Kennedy Journal: BMJ Open Date: 2016-10-21 Impact factor: 2.692
Authors: Peter J Gates; Melissa T Baysari; Virginia Mumford; Magdalena Z Raban; Johanna I Westbrook Journal: Drug Saf Date: 2019-08 Impact factor: 5.606